examined the adequacy of different drugs for primal therapy on each type of pollinosis. Methods: Patients with pollinosis attending 11 otorhinolaryngology clinics in Tokyo during part of pollen season were enrolled and assigned to either an anti-leukotriene agent (pranlukast) or an antihistamine based on their symptoms in the previous year. During 3 months of treatment, symptoms and quality of life (QOL) were investigated by a mail questionnaire at 7 time points (at the start of treatment, and between March 1 and May 15). Results: Of 150 patients with pollinosis who were registered, analysis was conducted on 144 patients (62 receiving anti-leukotriene therapy and 82 receiving antihistamine therapy), excluding those with incomplete questionnaires. In both groups, scores for symptoms of pollinosis and QOL were low, suggesting that both drugs were effective considering the high pollen levels season (5-9 times higher than the previous year). After defining types of pollinosis by the severity of symptoms (sneezing, rhinorrhea, or nasal blockage), stratified analysis was conducted. This showed that antihistamine therapy was effective for the sneezing/rhinorrhea type and anti-leukotriene therapy was effective for the nasal blockage type, with no difference between the 2 drugs the combined type. For the nasal blockage type, symptoms and QOL improved faster with anti-leukotriene than antihistamine therapy from the peak to the end of the pollen season. No adverse effects were observed. Conclusions: When either an anti-leukotriene (pranlukast) or an antihistamine was used for primal therapy of pollinosis, both drugs improved pollinosis symptoms and QOL. Stratified analysis showed that the antihistamine was more effective for the sneezing/rhinorrhea type and the antileukotriene was more effective for the nasal blockage type, with no difference in effectiveness for the combined type. Therefore, appropriate drugs for the type of pollinosis should be selected for primal therapy. Background: There are several factors that could produce olfactory dysfunction. The chronic inflammation of the upper air tract, especially allergic rhinitis is mentioned as a trigger factor. The aim of this study is assess the prevalence and identify clinical features associated with olfactory dysfunction in patients with chronic rhinosinusitis. Methods: A prospective, analytical and observational study in adult patients (. 18 years) with chronic rhinosinusitis during the period May-October of 2010. We used the CCCRC (Connecticut Chemosensory Clinical Research Center smell test) Results: A total of 33 patients were investigated. In the group of patients between 18 and 39 years, 73% of patients suffer from hyposmia and 18% anosmia; for the group of 40 to 64 years, 63% with hyposmia and 37% anosmia; patients older than 65 years, 67% hyposmia and 33% with anosmia. In the smokers group the 11% of patient presented hyposmia and 13% anosmia (P , 0.05); 5% in both cases had a history of nasal endoscopic surgery. In patients with chronic rhinosinusitis with nasal polyps have 18% with hyposmia and 19% with anosmia (P , 0.05). A 20% with allergic rhinitis had hyposmia while anosmia in 22% (P , 0.05). Septal deviation patients had 20% of hyposmia (P , 0.001) and 12% anosmia. Patients with turbinate hypertrophy had 22% hyposmia (P , 0.001) and 13% anosmia while in the group of patients with Asthma, the 4% had hyposmia and 16% anosmia (P , 0.001). Conclusions: Nasal polyposis, septal deviation, turbinate hypertrophy, smoke, allergic rhinitis and asthma are negative predictors factors of olfactory dysfunction in patients with CRS. A previous endoscopic surgery, age and sex would not intervene in the olfactory loss. Background: To understand the perceptions of caregivers of patients with cow milk allergy (CMA) regarding the disease and its treatment. Methods: Qualitative study in which caregivers of children and adolescents with confirmed CMA followed, at least, for 1 year, were interviewed. They were recruited from outpatient clinic of Allergy and Immunology Division from a tertiary pediatric hospital in São Paulo, Brazil. The interviews were conducted under conditions of privacy and 2 opened questions were proposed: "Tell me about your experience with cow's milk allergy treatment" and "What do you expect from your child's disease treatment?" Data were audio-recorded, transcribed, analyzed using the content analysis method and categories and subcategories were generated based on their speeches.
Background: There are several factors that could produce olfactory dysfunction. The chronic inflammation of the upper air tract, especially allergic rhinitis is mentioned as a trigger factor. The aim of this study is assess the prevalence and identify clinical features associated with olfactory dysfunction in patients with chronic rhinosinusitis. Methods: A prospective, analytical and observational study in adult patients (. 18 years) with chronic rhinosinusitis during the period May-October of 2010. We used the CCCRC (Connecticut Chemosensory Clinical Research Center smell test) Results: A total of 33 patients were investigated. In the group of patients between 18 and 39 years, 73% of patients suffer from hyposmia and 18% anosmia; for the group of 40 to 64 years, 63% with hyposmia and 37% anosmia; patients older than 65 years, 67% hyposmia and 33% with anosmia. In the smokers group the 11% of patient presented hyposmia and 13% anosmia (P , 0.05); 5% in both cases had a history of nasal endoscopic surgery. In patients with chronic rhinosinusitis with nasal polyps have 18% with hyposmia and 19% with anosmia (P , 0.05). A 20% with allergic rhinitis had hyposmia while anosmia in 22% (P , 0.05). Septal deviation patients had 20% of hyposmia (P , 0.001) and 12% anosmia. Patients with turbinate hypertrophy had 22% hyposmia (P , 0.001) and 13% anosmia while in the group of patients with Asthma, the 4% had hyposmia and 16% anosmia (P , 0.001). Conclusions: Nasal polyposis, septal deviation, turbinate hypertrophy, smoke, allergic rhinitis and asthma are negative predictors factors of olfactory dysfunction in patients with CRS. A previous endoscopic surgery, age and sex would not intervene in the olfactory loss. Background: To understand the perceptions of caregivers of patients with cow milk allergy (CMA) regarding the disease and its treatment. Methods: Qualitative study in which caregivers of children and adolescents with confirmed CMA followed, at least, for 1 year, were interviewed. They were recruited from outpatient clinic of Allergy and Immunology Division from a tertiary pediatric hospital in São Paulo, Brazil. The interviews were conducted under conditions of privacy and 2 opened questions were proposed: "Tell me about your experience with cow's milk allergy treatment" and "What do you expect from your child's disease treatment?" Data were audio-recorded, transcribed, analyzed using the content analysis method and categories and subcategories were generated based on their speeches. Results: Nine interviews were done and 3 categories with subcategories emerged: A. Treatment and education of the patient and their caregivers (life experiences, bases of treatment, coping with the disease). B. Resolution of the disease (hope, gradual improvement). C. Quality of life (social inclusion, family daily activities, costs of dietary treatment). Caregivers experienced difficulties during the initial treatment but pointed out that the guidance given during follow-up made the adjustments easier. They also compared CMA with other chronic diseases and highlighted the importance of their children follow-up in this institution for adequate control. They commented on the difficulties about lack of cooperation from other family members regarding the restrictive diet, their experience coping with allergic reactions, doubts about the treatment and gaps on knowledge about the disease by other physicians and people. The majority of relatives was satisfied with the gradual improvement of patients, although there are no drugs or vaccines for treatment, and observed a reduction on the severity of symptoms and tolerance of milk traces. In addition, they commented on the efforts to give a normal life for their children, the changes in their daily lives and the difficulty to buy special products. Conclusions: This qualitative study allowed us to understand how families cope with the disease, their histories and hopes about the treatment. They feel a great burden of the disease and need support and orientation from health professionals.
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